Auris Medical Holding AG, of Zug, Switzerland, said it extended its collaboration with King's College London, which is focused on the discovery of small-molecule compounds for a second-generation tinnitus treatment. It allows for further development with the aim of selecting a lead compound for the AM-102 tinnitus program by the end of this year.